<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048825</url>
  </required_header>
  <id_info>
    <org_study_id>CLSYN.1702</org_study_id>
    <secondary_id>OASIS-9</secondary_id>
    <nct_id>NCT03048825</nct_id>
  </id_info>
  <brief_title>Colchicine and Spironolactone in Patients With MI / SYNERGY Stent Registry</brief_title>
  <acronym>CLEAR SYNERGY</acronym>
  <official_title>A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients With Myocardial Infarction / SYNERGY Stent Registry - Organization to Assess Strategies for Ischemic Syndromes 9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BSC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat&#xD;
      myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY&#xD;
      stent) as well as the non-culprit arteries (randomization to routine colchicine and&#xD;
      spironolactone).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, international SYNERGY stent registry that is embedded within a&#xD;
      randomized, blinded, double-dummy, 2x2 factorial design trial of colchicine versus placebo&#xD;
      and spironolactone versus placebo in patients with myocardial infarction who have undergone&#xD;
      primary percutaneous coronary intervention (PCI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-dummy masking of colchicine and spironolactone in 2x2 factorial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Major Adverse Cardiac Events (MACE) for SYNERGY Stent (defined as the composite of death, recurrent target vessel MI, stroke, or ischemia driven target vessel revascularization) compared to performance goal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of cardiovascular death, recurrent myocardial infarction, or stroke</measure>
    <time_frame>through study completion, an estimated average of 2 years</time_frame>
    <description>The first occurrence of cardiovascular death, recurrent myocardial infarction, or stroke in the colchicine comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of cardiovascular death or new or worsening heart failure</measure>
    <time_frame>through study completion, an estimated average of 2 years</time_frame>
    <description>The first occurrence of cardiovascular death or new or worsening heart failure in the spironolactone comparison</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Non ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.&#xD;
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine-placebo tablet + Spironolactone 25 mg tablet.&#xD;
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.&#xD;
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Colchicine-placebo tablet + Spironolactone-placebo tablet.&#xD;
Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.5 mg twice daily</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Spironolactone 25 mg once daily</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY Bioabsorbable Polymer Drug-Eluting Stent</intervention_name>
    <description>Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.</description>
    <arm_group_label>Colchicine + Spironolactone +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine-Placebo</intervention_name>
    <description>Matching Colchicine-placebo twice daily</description>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Spironolactone +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone-Placebo</intervention_name>
    <description>Matching Spironolactone-Placebo once daily</description>
    <arm_group_label>Colchicine +/- SYNERGY Stent</arm_group_label>
    <arm_group_label>Placebo +/- SYNERGY Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. a) Patients with STEMI referred for PCI within 12 hours of symptom onset, have a&#xD;
             culprit lesion amenable to stenting, and with planned SYNERGY stent implantation for&#xD;
             SYNERGY registry&#xD;
&#xD;
             OR&#xD;
&#xD;
             b) Patients with STEMI referred for PCI within 48 hours of symptom onset, not&#xD;
             prospectively enrolled in SYNERGY stent registry&#xD;
&#xD;
             OR&#xD;
&#xD;
             c) Patients with diagnosis of Non STEMI with ischemic symptoms and either Hs Troponin&#xD;
             &gt; or = 300x ULN or Troponin &gt; or = 200x ULN who have undergone PCI with one of the&#xD;
             following:&#xD;
&#xD;
             i. LVEF&lt; or =45% ii. Diabetes iii. Multivessel CAD defined as 50% stenosis in 2nd&#xD;
             major epicardial vessel iv. Prior MI&#xD;
&#xD;
          2. Able to be enrolled/randomized within 72 hours of index PCI (however patients should&#xD;
             be randomized as soon as possible after PCI)&#xD;
&#xD;
          3. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age ≤18 years&#xD;
&#xD;
          2. Pregnancy, breastfeeding, or women of childbearing potential who are not using an&#xD;
             effective method of contraception&#xD;
&#xD;
          3. Any medical, geographic, or social factor making study participation impractical or&#xD;
             precluding required follow-up&#xD;
&#xD;
          4. Systolic blood pressure &lt;90 mm Hg&#xD;
&#xD;
          5. Active diarrhea&#xD;
&#xD;
          6. Known allergy or contraindication to everolimus, the SYNERGY stent or any of its&#xD;
             components&#xD;
&#xD;
          7. Unable to receive dual antiplatelet therapy&#xD;
&#xD;
          8. Any contraindication or known intolerance to colchicine or spironolactone&#xD;
&#xD;
          9. Requirement for colchicine or mineralocorticoid antagonist for another indication&#xD;
&#xD;
         10. History of cirrhosis or current severe hepatic disease&#xD;
&#xD;
         11. Current or planned use of any of: cyclosporine, verapamil, HIV protease inhibitors,&#xD;
             azole antifungals, or macrolide antibiotics&#xD;
&#xD;
         12. Creatinine clearance &lt;30 mL/min/1.73 m2&#xD;
&#xD;
         13. Serum Potassium &gt;5.0 meq/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjit S Jolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa McClelland</last_name>
    <phone>9055274322</phone>
    <phone_ext>41079</phone_ext>
    <email>clear@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Tyrwhitt</last_name>
    <phone>9055274322</phone>
    <email>clear@phri.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CLEAR Investigator</last_name>
      <phone>9055274322</phone>
      <email>clear@phri.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

